BioCryst Pharmaceuticals (NASDAQ:BCRX) Given “In-Line” Rating at Evercore ISI

Evercore ISI restated their in-line rating on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) in a research note issued to investors on Wednesday morning, MarketBeat.com reports. The brokerage currently has a $8.00 target price on the biotechnology company’s stock.

Several other equities research analysts have also recently commented on the stock. Royal Bank Of Canada reissued an “outperform” rating and set a $13.00 price target on shares of BioCryst Pharmaceuticals in a research report on Monday, June 30th. Bank of America boosted their price target on shares of BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Tuesday, July 1st. Wedbush boosted their price target on shares of BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the stock an “outperform” rating in a research report on Monday, June 30th. Wall Street Zen raised shares of BioCryst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 26th. Finally, Needham & Company LLC reissued a “buy” rating and set a $17.00 price target on shares of BioCryst Pharmaceuticals in a research report on Monday, August 4th. Eight equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, BioCryst Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $16.30.

BioCryst Pharmaceuticals Trading Down 2.9%

Shares of NASDAQ BCRX opened at $7.37 on Wednesday. The firm has a market cap of $1.55 billion, a PE ratio of -40.94, a PEG ratio of 1.53 and a beta of 1.05. BioCryst Pharmaceuticals has a 1-year low of $6.01 and a 1-year high of $11.31. The company has a fifty day moving average price of $8.16 and a 200 day moving average price of $8.70.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings results on Monday, August 4th. The biotechnology company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.03 by $0.12. The business had revenue of $163.35 million for the quarter, compared to the consensus estimate of $149.59 million. During the same period last year, the firm earned ($0.06) earnings per share. The company’s quarterly revenue was up 49.5% compared to the same quarter last year. Equities research analysts forecast that BioCryst Pharmaceuticals will post -0.36 EPS for the current year.

Insider Buying and Selling

In related news, Director Theresa Heggie sold 70,000 shares of the company’s stock in a transaction dated Wednesday, August 13th. The shares were sold at an average price of $8.51, for a total value of $595,700.00. Following the transaction, the director owned 65,352 shares in the company, valued at approximately $556,145.52. This represents a 51.72% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 5.10% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Osaic Holdings Inc. grew its position in shares of BioCryst Pharmaceuticals by 10.1% during the 2nd quarter. Osaic Holdings Inc. now owns 48,611 shares of the biotechnology company’s stock worth $436,000 after purchasing an additional 4,466 shares in the last quarter. Headlands Technologies LLC grew its position in shares of BioCryst Pharmaceuticals by 1,208.9% during the 2nd quarter. Headlands Technologies LLC now owns 55,221 shares of the biotechnology company’s stock worth $495,000 after purchasing an additional 51,002 shares in the last quarter. CANADA LIFE ASSURANCE Co grew its position in shares of BioCryst Pharmaceuticals by 20.5% during the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 60,906 shares of the biotechnology company’s stock worth $546,000 after purchasing an additional 10,361 shares in the last quarter. Tower Research Capital LLC TRC grew its position in shares of BioCryst Pharmaceuticals by 213.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 21,758 shares of the biotechnology company’s stock worth $195,000 after purchasing an additional 14,822 shares in the last quarter. Finally, Exome Asset Management LLC grew its position in shares of BioCryst Pharmaceuticals by 185.3% during the 2nd quarter. Exome Asset Management LLC now owns 172,883 shares of the biotechnology company’s stock worth $1,549,000 after purchasing an additional 112,283 shares in the last quarter. Institutional investors and hedge funds own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.